Google DeepMind founder says AI could cure all disease by 2035
AI is already designing drugs and vaccines in minutes, genetic therapies in hours, which makes this achievable. But access to those cures is a different matter ...
Key takeaways
- While the boon and bane is still a big debate, Google DeepMind CEO Demis Hassabis highlights the goodness of AI tools.
- In a recent interview, Hassabis emphasised that AI will be able to cure all diseases in another 10 years which may be possible given the speed at which it’s been able to develop new novel drugs.
- In his claims, he indicated that AI will not just cure but will be the end of all diseases.
Cite or link to this article
Griffin, M. (2025) 'Google DeepMind founder says AI could cure all disease by 2035', 311 Institute, 19 November. Available at: https://www.311institute.com/google-deepmind-founder-says-ai-could-cure-all-disease-by-2035/ (Accessed: 1 October 2026).
There is no doubt that Artificial Intelligence (AI) will play a crucial role in every industry. While the boon and bane is still a big debate, Google DeepMind CEO Demis Hassabis highlights the goodness of AI tools. In a recent interview, Hassabis emphasised that AI will be able to cure all diseases in another 10 years which may be possible given the speed at which it’s been able to develop new novel drugs.
In his claims, he indicated that AI will not just cure but will be the end of all diseases. Speaking during the CBS' 60 Minutes interview Hassabis said, “So, on average, it takes, you know, ten years and billions of dollars to design just one drug. We can maybe reduce that from years to maybe months or maybe even weeks. Which sounds incredible today, but that's also what people used to think about protein structures. And it would revolutionise human health, and I think one day maybe we can cure all diseases with the help of AI.”
The Future of Healthcare and Clinical Trials, by Futurist Matthew Griffin
When questioned about whether AI could eventually eliminate all diseases, the 48-year-old British scientist replied, “I think that's within reach. Maybe within the next decade or so, I don't see why not.”
In fact, DeepMind’s AlphaFold model astonishingly mapped over 200 million protein structures within a single year—a feat that, according to Hassabis, would have otherwise taken “a billion years of PhD time.” He emphasised that grasping these structures is crucial for uncovering how diseases function and for crafting precisely targeted treatments.
“If we know the function, then we can understand what goes wrong in disease... And we can design drugs and molecules that will bind to the right part of the surface of the protein.”
As soon as the video went live, it was flooded with different type of reaction. On the same note, the rival, CEO of Perplexity AI, Aravind Srinivas, has also praised Hassabis, calling him a "genius". He also proposed that to achieve this claim, Hassabis should be given all the resources in the world.
Out of courtesy, Hassabis replied "Thanks Aravind."
FAQ
Why does this matter?
AI is already designing drugs and vaccines in minutes, genetic therapies in hours, which makes this achievable. But access to those cures is a different matter ...
About the author
Matthew Griffin Founder, 311 Institute
Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath."
Read full bio
Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath." 15-time best selling author of the "Codex of the Future" series, Matthew is the Founder and Futurist in Chief of the 311 Institute, a global Futures and Deep Futures advisory firm working with royal households, world leaders, G7, G20, and G77 governments, NGOs, and multi-national mid and mega cap firms to help them explore, shape, and lead the next 50 years of business and society.
An award-winning YouTube creator with over a million followers, with an unrivalled global reach and impact, Matthew is a highly sought-after international keynote speaker, lecturer, and mentor who collaborates with global leaders through the United Nations Alliance of Civilizations (UNAOC) and United Nations General Assembly (UNGA) to shape pivotal initiatives such as the UN’s AI for Humanity program, the United Nations Conference of the Parties (UN COP), and the World Economic Forum in Davos.
As the former Global Head of Cloud, National Security, and Enterprise Sales for companies including Atos, Dell-EMC, and IBM, Matthew has a proven track record of building multi-billion dollar business units and turning failing divisions into market leaders. His ability to identify, analyse, and communicate the implications of hundreds of emerging technologies and trends is unparalleled, and his insights are trusted by many of the world’s most respected organisations, including ABB, Accenture, Adidas, AON, ARM, BCG, Centrica, Citi, Coca-Cola, Dentons, Deloitte, Dow Jones, EY, Google, KPMG, Lego, Legal & General, LinkedIn, Microsoft, PepsiCo, Qualcomm, RWE, Samsung, Siemens AG and Siemens Energy, T-Mobile, UBS, VISA, Walmart, Workday, Worldpay and many others.
Regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, Matthews mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.
What future do you need to see?
Choose one to get started on biotech and enhanced humans and the future of your organisation.
Source: first published by the 311 Institute on 19 November 2025. Cite as: Griffin, M. (2025). Google DeepMind founder says AI could cure all disease by 2035. 311 Institute. https://www.311institute.com/google-deepmind-founder-says-ai-could-cure-all-disease-by-2035/
You are welcome to quote this article with credit and a link to the original.